-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Despite advances in diagnosis and treatment, the 5-year survival rate of hepatocellular carcinoma patients after diagnosis is less than 15%, making liver cancer the fourth leading cause of cancer death in the world
.
At present, for patients with advanced hepatocellular carcinoma, immune checkpoint inhibitor combined with anti- vascular therapy has become one of the main treatment methods
.
Despite advances in diagnosis and treatment, the 5-year survival rate of hepatocellular carcinoma patients after diagnosis is less than 15%, making liver cancer the fourth leading cause of cancer death in the world
The study included patients from Europe, North America, and Asia.
Early antibiotic exposure was defined as the use of antibiotics (EIOP) within 30 days before immunotherapy or within 30 days (-30 to +30 days) after treatment
The study included patients from Europe, North America, and Asia.
The study included 449 patients with hepatocellular carcinoma who received immunotherapy (ICI) treatment in 12 centers, including the United States (n = 250, 55%), Europe (n = 109, 26%) and Asia (n = 91, 20%) )
After a median follow-up of 17.
The ORR of the EIOP and non-EIOP groups were 20.
Prognosis
PrognosisMultivariate analysis found that EIOP was an independent prognostic factor of PFS (0.
75 (0.
Multivariate analysis found that EIOP was an independent prognostic factor of PFS (0.
Multivariate analysis of prognostic factors
Multivariate analysis of prognostic factorsIn summary, studies have shown that the use of early antibiotics (ATB) in patients with hepatocellular carcinoma (30 days before ICI treatment or within 30 days after treatment) may benefit from immunotherapy, which is worthy of further study
.
In summary, studies have shown that the use of early antibiotics (ATB) in patients with hepatocellular carcinoma (30 days before ICI treatment or within 30 days after treatment) may benefit from immunotherapy, which is worthy of further study
Original source:
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al.
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.
Liver Cancer.
DOI: 10.
1159/000519108.
Published online: October 8, 2021.
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma Liver Cancer DOI:.
.
10.
1159 / 000519108 Published online:.
October 8, 2021 in this message
